The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...